Moderna: Vaccine Efficacy Against COVID-19 Was 94.1%
^ Added at
{{ hourTwoDigit }}:{{ minuteTwoDigit }}
^ Added at
{{ hourTwoDigit }}:{{ minuteTwoDigit }}
^ Added at
{{ hourTwoDigit }}:{{ minuteTwoDigit }}
^ Added at
{{ hourTwoDigit }}:{{ minuteTwoDigit }}
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use
From investors.modernatx.com